Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00457275 | Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070) | PHASE3 | COMPLETED | 440 | — | — | Apr 1, 2005 | Nov 1, 2005 | Aug 15, 2024 | - | — |
| NCT00395473 | Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED) | PHASE3 | COMPLETED | 141 | — | — | Mar 1, 2005 | Nov 1, 2005 | May 10, 2024 | - | — |
| NCT00092612 | Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED) | PHASE3 | COMPLETED | 372 | — | — | May 1, 2003 | Jun 1, 2004 | Aug 15, 2024 | - | — |
| NCT00092638 | An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED) | PHASE3 | COMPLETED | 450 | — | — | May 1, 2003 | Aug 1, 2004 | Aug 15, 2024 | - | — |
| NCT00092573 | Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED) | PHASE3 | COMPLETED | 576 | — | — | Apr 1, 2003 | Nov 1, 2004 | Aug 15, 2024 | - | — |
| NCT00092625 | Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803) | PHASE3 | COMPLETED | 442 | — | — | Mar 1, 2003 | Aug 1, 2004 | Aug 15, 2024 | - | — |
| NCT00092599 | Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801) | PHASE3 | COMPLETED | 410 | — | — | Feb 1, 2003 | Jul 1, 2004 | Aug 15, 2024 | - | — |
| NCT00092560 | Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036) | PHASE3 | COMPLETED | 587 | — | — | Dec 1, 2002 | Dec 1, 2003 | Aug 15, 2024 | - | — |
| NCT00092586 | Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040) | PHASE3 | COMPLETED | 2,904 | — | — | Sep 1, 2002 | Oct 1, 2003 | Aug 15, 2024 | - | — |
| Name | Type | Description |
|---|---|---|
| MK0653, ezetimibe / Duration of Treatment: 4 Weeks | DRUG | - |
| MK0653, ezetimibe / Duration of Treatment: 6 Weeks | DRUG | - |
| MK0653, ezetimibe | DRUG | - |
| Comparator: ezetimibe, placebo | DRUG | - |
| Comparator: fenofibrate monotherapy | DRUG | - |
| Comparator: statins | DRUG | - |
Inclusion Criteria: * Men or women \>18 and \<80 years of age * Patients receiving statin therapy for a minimum period of 6 weeks prior to visit 1 * Female patients receiving hormone therapy (including hormone replacement therapy, any estrogen antagonist/agonist, or oral contraceptives) if maintain...